Patient-based strategy for systemic treatment of metastatic renal cell carcinoma
H Kirchner, D Strumberg, A Bahl… - Expert Review of …, 2010 - Taylor & Francis
There were only a few options 3 years ago to treat metastatic renal cell carcinoma (mRCC),
a disease with a very poor prognosis. With the approval of targeted therapies for mRCC …
a disease with a very poor prognosis. With the approval of targeted therapies for mRCC …
Patient-based strategy for systemic treatment of metastatic renal cell carcinoma
H Kirchner, D Strumberg, A Bahl… - Expert review of …, 2010 - pubmed.ncbi.nlm.nih.gov
There were only a few options 3 years ago to treat metastatic renal cell carcinoma (mRCC),
a disease with a very poor prognosis. With the approval of targeted therapies for mRCC …
a disease with a very poor prognosis. With the approval of targeted therapies for mRCC …
Patient-based strategy for systemic treatment of metastatic renal cell carcinoma.
H Kirchner, D Strumberg, A Bahl… - Expert Review of …, 2010 - europepmc.org
There were only a few options 3 years ago to treat metastatic renal cell carcinoma (mRCC),
a disease with a very poor prognosis. With the approval of targeted therapies for mRCC …
a disease with a very poor prognosis. With the approval of targeted therapies for mRCC …
[PDF][PDF] Patient-based strategy for systemic treatment of metastatic renal cell carcinoma
H Kirchner, D Strumberg, A Bahl… - Expert Rev. Anticancer …, 2010 - researchgate.net
There were only a few options 3 years ago to treat metastatic renal cell carcinoma (mRCC),
a disease with a very poor prognosis. With the approval of targeted therapies for mRCC …
a disease with a very poor prognosis. With the approval of targeted therapies for mRCC …
Patient-based strategy for systemic treatment of metastatic renal cell carcinoma
H Kirchner, D Strumberg, A Bahl… - Expert Review of …, 2010 - go.gale.com
Renal cancer was expected to account for 4.2% of all new cancers, and the mortality was
12.980 in the USA in 2009 [1]. Of these cancers, 85% arise from the renal epithelium and are …
12.980 in the USA in 2009 [1]. Of these cancers, 85% arise from the renal epithelium and are …
Patient-based strategy for systemic treatment of metastatic renal cell carcinoma
H Kirchner, D Strumberg, A Bahl… - Expert Review of …, 2010 - search.proquest.com
There were only a few options 3 years ago to treat metastatic renal cell carcinoma (mRCC),
a disease with a very poor prognosis. With the approval of targeted therapies for mRCC …
a disease with a very poor prognosis. With the approval of targeted therapies for mRCC …